| 1.14 -0.01 (-0.87%) | 04-24 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.4  |
1-year : | 1.5 |
| Resists | First : | 1.2 |
Second : | 1.28 |
| Pivot price | 1.18 |
|||
| Supports | First : | 1.06 |
Second : | 0.88 |
| MAs | MA(5) : | 1.14 | MA(20) : | 1.16 |
| MA(100) : | 1.2 |
MA(250) : | 1.2 |
|
| MACD | MACD : | -0.1 |
Signal : | 0 |
| %K %D | K(14,3) : | 32.6 |
D(3) : | 35.8 |
| RSI | RSI(14): 46.1 |
|||
| 52-week | High : | 1.88 | Low : | 0.97 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ CODX ] has closed above bottom band by 22.4%. Bollinger Bands are 34.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.18 - 1.19 | 1.19 - 1.19 |
| Low: | 1.11 - 1.12 | 1.12 - 1.13 |
| Close: | 1.13 - 1.14 | 1.14 - 1.15 |
Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. It offers polymerase chain reaction (PCR) diagnostic tests for COVID-19, tuberculosis, hepatitis B and C, human papilloma virus, malaria, chikungunya, dengue, and the zika virus; three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; and molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications. The company also provides tests that identify genetic traits in plant and animal genomes; and portable PCR device designed to bring PCR to patients in point-of-care and at-home settings. In addition, it intends to sell diagnostic equipment from other manufacturers as self-contained lab systems. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
Wed, 24 Apr 2024
Co-Diagnostics, Inc. to Host Booth and Deliver Presentation at APRC 2024 in Taiwan - PR Newswire
Mon, 22 Apr 2024
Is Co-Diagnostics (CODX) Stock Outpacing Its Medical Peers This Year? - Yahoo Movies Canada
Fri, 12 Apr 2024
Co-Diagnostics, Inc. Inaugurates New Manufacturing Facility in Utah with Ribbon Cutting Event - PR Newswire
Thu, 04 Apr 2024
Co-Diagnostics, Inc. Appoints New President and Other C-Level Positions - Nasdaq
Thu, 21 Mar 2024
Co-Diagnostics, Inc. CEO Delivers Manufacturing and Commercialization Update in Conference Keynote Address - PR Newswire
Fri, 15 Mar 2024
Co-Diagnostics Inc Welcomes Richard Abbott as New President - TipRanks.com - TipRanks
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 31 (M) |
| Shares Float | 30 (M) |
| Held by Insiders | 2.6 (%) |
| Held by Institutions | 15.6 (%) |
| Shares Short | 497 (K) |
| Shares Short P.Month | 341 (K) |
| EPS | -1.21 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.75 |
| Profit Margin | 0 % |
| Operating Margin | -332.7 % |
| Return on Assets (ttm) | -24.5 % |
| Return on Equity (ttm) | -35.3 % |
| Qtrly Rev. Growth | 153.6 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0.21 |
| EBITDA (p.s.) | -1.33 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -22 (M) |
| Levered Free Cash Flow | -9 (M) |
| PE Ratio | -0.95 |
| PEG Ratio | 0 |
| Price to Book value | 0.41 |
| Price to Sales | 5.23 |
| Price to Cash Flow | -1.62 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|